Safety of Phosphodiesterase-5 Inhibitors in Valvular Heart Disease

Aaron Gopal, Tarun Sharma, Joe B. Calkins

Research output: Contribution to journalReview articlepeer-review


Erectile dysfunction is a common entity in clinical practice. Primary erectile dysfunction, not related to vasculopathy or psychiatric disorder, can be readily treated with phosphodiesterase inhibitors. These drugs have many physiologic effects that can alter a patient's hemodynamic profile considerably, especially in the presence of concomitant structural heart disease, specifically valvular heart disease. Although some contraindications to the use of PDE5 inhibitors in patients with cardiovascular disease are defined, the effect of these drugs in the presence of valvular heart disease is not well documented. The purpose of this review is to analyze the data regarding the safety of PDE5 inhibitors in patients with valvular heart disease.

Original languageEnglish (US)
Pages (from-to)372-376
Number of pages5
JournalJournal of Cardiovascular Pharmacology
Issue number3
StatePublished - Sep 3 2021
Externally publishedYes


  • Valvular heart disease
  • pharmacologic safety
  • phosphodiesterase inhibitors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology


Dive into the research topics of 'Safety of Phosphodiesterase-5 Inhibitors in Valvular Heart Disease'. Together they form a unique fingerprint.

Cite this